References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCaractéristiques cliniques des sujets répondeurs à la vibrotonie corporelle totale
Beaudart, Charlotte ULg; Buckinx, Fanny ULg; Maquet, Didier ULg et al

in Cahiers de l'Année Gérontologique (Les) (2013, September), 5(1-2), 118-119

Detailed reference viewed: 27 (10 ULg)
Full Text
Peer Reviewed
See detailImportance du déficit en vitamine D chez les femmes françaises ostéoporotiques et ostéopéniques âgées de plus de 80 ans
Bruyère, Olivier ULg; Slomian, Justine ULg; Beaudart, Charlotte ULg et al

in Cahiers de l'Année Gérontologique (Les) (2013, September), 5(1-2), 75

Detailed reference viewed: 44 (22 ULg)
Full Text
Peer Reviewed
See detailLes effets d'une supplémentation en vitamine D sur la force musculaire : une méta-analyse d'essais randomisés contrôlés
Beaudart, Charlotte ULg; Buckinx, Fanny ULg; Rabenda, Véronique ULg et al

in Cahiers de l'Année Gérontologique (Les) (2013, September), 5(1-2), 38

Detailed reference viewed: 36 (11 ULg)
Full Text
Peer Reviewed
See detailQuality of life in sarcopenia and frailty
Rizzoli, René; Reginster, Jean-Yves ULg; Arnal, Jean-François et al

in Calcified Tissue International (2013), 93

The reduced muscle mass and impaired muscle performance that define sarcopenia in older individuals are associated with increased risk of physical limitation and a variety of chronic diseases. They may ... [more ▼]

The reduced muscle mass and impaired muscle performance that define sarcopenia in older individuals are associated with increased risk of physical limitation and a variety of chronic diseases. They may also contribute to clinical frailty. A gradual erosion of quality of life (QoL) has been evidenced in these individuals, although much of this research has been done using generic QoL instruments, particularly the SF-36, which may not be ideal in older populations with significant comorbidities. This review and report of an expert meeting presents the current definitions of these geriatric syndromes (sarcopenia and frailty). It then briefly summarizes QoL concepts and specificities in older populations and examines the relevant domains of QoL and what is known concerning QoL decline with these conditions. It calls for a clearer definition of the construct of disability, argues that a disease-specific QoL instrumentfor sarcopenia/frailty would be an asset for future research, and discusses whether there are available and validated components that could be used to this end and whether the psychometric properties of these instruments are sufficiently tested. It calls also for an approach using utility weighting to provide some cost estimates and suggests that a time trade-off study could be appropriate. [less ▲]

Detailed reference viewed: 36 (15 ULg)
Full Text
Peer Reviewed
See detailPlatelet-rich plasma (PRP) to treat chronic upper patellar tendinopathies
Kaux, Jean-François ULg; Croisier, Jean-Louis ULg; Bruyère, Olivier ULg et al

in British Journal of Sports Medicine (2013, July), 47(10 (e3)), 15

Background: Upper patellar tendinopathies remain often chronic and rebel to a thorough conservative treatment. Moreover, the option of a surgical treatment could be disappointing. New treatments are being ... [more ▼]

Background: Upper patellar tendinopathies remain often chronic and rebel to a thorough conservative treatment. Moreover, the option of a surgical treatment could be disappointing. New treatments are being developed. Injection of PRP is one of these. Platelets contain lot of growth factors which would have the potentiality to enhance the healing process of tendons. Even if in vitro and animal experiments have demonstrated this stimulation of tendon healing process1, clinical series are subject to controversy2. Methods: Twenty patients with chronic upper patellar tendinopathy were enrolled. Assessments [VAS, clinical examination with an algometer, algofunctional scores (IKDC and VISA-P), functional assessments (isokinetic and Optojump) and imagery (ultrasounds and MRI)]were made before infiltration of PRP, and 6 weeks and 3 months after. The PRP was obtained by an apheresis system (COM.TEC, Fresenius). Six millilitres of PRP were injected without local anaesthetic. One week after infiltration, patients started a 6-week standardised sub-maximal eccentric reeducation. Results: We observed a very significant improvement of the algofunctional status as soon as 6 weeks after the infiltration of PRP, and continued to a lesser extent up to 3 months. During functional evaluation, pain decreased as well, but without significant improvement of performances. No significant improvements in the imagery were observed. Interestingly, patients who had a VAS equal or below 1 after 3 months post-infiltration were younger (24.7 vs 32.2 y.o.). Moreover, these younger patients had a significant increase of the IKDC score (p=0.003), a significant improvement of pain during isokinetic evaluations (p<0.05), and during Optojump assessments (p=0.01). Seventy-five percent of subjects were able to return to sport, even if only half of these patients recovered the same level than before the tendinopathy. Discussion / Conclusions: This study demonstrates that a local infiltration of PRP associated with a submaximal eccentric protocol is efficient to improve symptoms of chronic upper patellar tendinopathies, non-responsive to classical conservative treatments. However, up to now, there is no consensus on the method to prepare the PRP. Indeed, each technique could provide a very different PRP (variations in the platelet concentrations and of the amount of red and white cells). [less ▲]

Detailed reference viewed: 89 (24 ULg)
Full Text
Peer Reviewed
See detailHow to define responders in osteoarthritis
Cooper, Cyrus; Adachi, Jonathan D; Bardin, Thomas et al

in Current Medical Research & Opinion (2013), 29(6), 719-29

Background: Osteoarthritis is a clinical syndrome of failure of the joint accompanied by varying degrees of joint pain, functional limitation, and reduced quality of life due to deterioration of articular ... [more ▼]

Background: Osteoarthritis is a clinical syndrome of failure of the joint accompanied by varying degrees of joint pain, functional limitation, and reduced quality of life due to deterioration of articular cartilage and involvement of other joint structures. Scope: Regulatory agencies require relevant clinical benefit on symptoms and structure modification for registration of a new therapy as a disease-modifying osteoarthritis drug (DMOAD). An international Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and International Osteoporosis Foundation was convened to explore the current burden of osteoarthritis, review current regulatory guidelines for the conduct of clinical trials, and examine the concept of responder analyses for improving drug evaluation in osteoarthritis. Findings: The ESCEO considers that the major challenges in DMOAD development are the absence of a precise definition of the disease, particularly in the early stages, and the lack of consensus on how to detect structural changes and link them to clinically meaningful endpoints. Responder criteria should help identify progression of disease and be clinically meaningful. The ideal criterion should be sensitive to change over time and should predict disease progression and outcomes such as joint replacement. Conclusion: The ESCEO considers that, for knee osteoarthritis, clinical trial data indicate that radiographic joint space narrowing40.5mm over 2 or 3 years might be a reliable surrogate measure for total joint replacement. On-going research using techniques such as magnetic resonance imaging and biochemical markers may allow the identification of these patients earlier in the disease process [less ▲]

Detailed reference viewed: 25 (4 ULg)
Full Text
See detailSelective Serotonin Reuptake Inhibitor and Fracture: an epidemiologic perspective
Bruyère, Olivier ULg

in Proceedings of the 8th Interantional Congress (GIO) (2013, May)

Detailed reference viewed: 11 (3 ULg)
Full Text
Peer Reviewed
See detailReturn-To-Play criteria after hamstring injury: actual medicine practice in professional soccer
Delvaux, François ULg; Rochcongar, Pierre; Bruyère, Olivier ULg et al

Poster (2013, April 25)

Detailed reference viewed: 176 (14 ULg)
Full Text
Peer Reviewed
See detailComparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria
Bruyère, Olivier ULg; Fossi, Martin; Zegels, Brigitte ULg et al

in Rheumatology International (2013), 33(4), 973-8

To assess the number of anti-osteoporosis treatments that would be reimbursed by the Belgian social security if either FRAX or the current criteria were used to determine access to reimbursement. This is ... [more ▼]

To assess the number of anti-osteoporosis treatments that would be reimbursed by the Belgian social security if either FRAX or the current criteria were used to determine access to reimbursement. This is a retrospective study based on data from 1,000 women randomly selected from an outpatient hospital specialized in bone metabolism in Belgium. Proportions of potentially refunded treatments between FRAX and current criteria were compared. Out of the 1,000 women files, 890 have sufficient information to assess FRAX . In Belgium, current criteria include a bone mineral density (BMD) T score below -2.5 at the lumbar spine, the femoral neck or the total hip and/or at least a prevalent vertebral fracture. Using these criteria, 167 women (18.8 %) would have access to reimbursement. Using the criteria based on the validated Belgian FRAX tool, only 116 women (13.0 %) would have access to reimbursement, meaning that access to reimbursement based on FRAX criteria would reduce by 30 % the anti-osteoporosis drug expenses covered by the national social security. Interestingly, only 65 women out of the 116 (56.0 %) selected with the FRAX criteria were also selected with the current criteria of the national social security. A substantial proportion of individuals that would potentially receive a reimbursement for their treatment using the FRAX criteria do not have access to any refund for their treatment with the current criteria. Since patients identified with the FRAX tool are those with the highest risk profile for future fractures, reappraisals of treatment reimbursement guidelines are expected in Belgium. [less ▲]

Detailed reference viewed: 35 (19 ULg)
Full Text
Peer Reviewed
See detailSafety concerns with the long-term management of osteoporosis
Reginster, Jean-Yves ULg; Pelousse, Franz; Bruyère, Olivier ULg

in Expert Opinion on Drug Safety (2013), 12(4), 507-22

Introduction: Postmenopausal osteoporosis is a chronic disease that exerts a significant burden on both individuals and the community. Hence, there is a requirement for long-term treatment to be ... [more ▼]

Introduction: Postmenopausal osteoporosis is a chronic disease that exerts a significant burden on both individuals and the community. Hence, there is a requirement for long-term treatment to be associated with a positive benefit-risk balance. Areas covered: In this descriptive review, the long-term safety of calcitonin, selective estrogen receptor modulators (SERMs), bisphosphonates, denosumab and strontium ranelate was reviewed based on randomized controlled trials of 3 years or longer supplemented by extension study data and data from large, observational studies. Expert opinion: Rare adverse events become apparent with all currently available treatments for osteoporosis with long-term therapy. Due to the rarity of these adverse events and to the worldwide burden of osteoporosis, the benefit- risk balance remains in favor of the beneficial effects of treatment on an outcome rather than the probability of an adverse effect. No single antiosteoporosis agent is appropriate for all patients. Treatment decisions should be made on an individual basis, taking into account the relative benefits and risks in different patient populations. [less ▲]

Detailed reference viewed: 19 (9 ULg)
Full Text
Peer Reviewed
See detailPerception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX ) to assess the 10-year probability of fracture
Bruyère, Olivier ULg; Nicolet, Delphine ULg; Compère, Stéphanie et al

in Rheumatology International (2013), 33(4), 979-83

The FRAX tool that calculates the 10-year probability of having a fracture has recently been validated for Belgium. Little is known about the perception and knowledge that GPs have about this tool in ... [more ▼]

The FRAX tool that calculates the 10-year probability of having a fracture has recently been validated for Belgium. Little is known about the perception and knowledge that GPs have about this tool in their daily practice. A survey has been conducted as part of a screening campaign for various diseases. The primary objective of the present study was to assess the perception and the knowledge of the FRAX tool by GPs. The secondary objective was to assess the impact of an information brochure about the FRAX tool on these outcomes. The survey was sent to a sample of 700 GPs after only half of them had received the information brochure. The survey results show that, out of the 193 doctors who responded to the survey, one-third know the FRAX tool but less than 20 % use it in their daily clinical practice. Among those who use it, the FRAX tool is largely seen as a complementary but not as an essential tool in the diagnosis or in the management of osteoporosis. It appears that the brochure could improve the knowledge of the FRAX tool but it would not be more efficient on its use in daily practice than the other sources of information. At present, the use of the FRAX tool in Belgium is limited but an information brochure could have a positive impact on the knowledge of the FRAX tool. [less ▲]

Detailed reference viewed: 23 (11 ULg)
Full Text
Peer Reviewed
See detailRole of nutraceuticals in the symptomatic and structural management of osteoarthritis
Bruyère, Olivier ULg

in Osteoporosis International (2013, April), 24(Suppl.1), 82-83

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailNonpharmacological management
Bruyère, Olivier ULg

in Osteoporosis International (2013, April), 24(Suppl.1), 76

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailReproducibility of joint space width assessment when external calibration on the radiograph is missing
DEROISY, Rita ULg; Reginster, Jean-Yves ULg; Bruyère, Olivier ULg

in Osteoporosis International (2013, April), 24(Suppl.1), 379

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailValidity of the French hip and knee replacement expectations surveys
NEUPREZ, Audrey ULg; François, Garance ULg; Delcour, JP et al

in Osteoporosis International (2013, April), 24(Suppl.1), 374

Detailed reference viewed: 38 (19 ULg)
Full Text
Peer Reviewed
See detailEvaluation of the impact of a 6-month training by whole body vibration on the risk of falls among nursing home residents
Beaudart, Charlotte ULg; Buckinx, Fanny ULg; Demonceau, Marie ULg et al

in Osteoporosis International (2013, April), 24(Suppl.1), 246-247

Detailed reference viewed: 34 (13 ULg)